The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women
Objective Breast cancer (BC) is one of the most commonly diagnosed solid malignancies in women worldwide. Purpose Finding new non-invasive circulating diagnostic biomarkers will facilitate the early prediction of BC and provide valuable insight into disease progression and response to therapy using...
Gespeichert in:
Veröffentlicht in: | Journal of cancer research and clinical oncology 2023-07, Vol.149 (8), p.5437-5451 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 5451 |
---|---|
container_issue | 8 |
container_start_page | 5437 |
container_title | Journal of cancer research and clinical oncology |
container_volume | 149 |
creator | El-Toukhy, Safinaz E. El-Daly, Sherien M. Kamel, Mahmoud M. Nabih, Heba K. |
description | Objective
Breast cancer (BC) is one of the most commonly diagnosed solid malignancies in women worldwide.
Purpose
Finding new non-invasive circulating diagnostic biomarkers will facilitate the early prediction of BC and provide valuable insight into disease progression and response to therapy using a safe and more accessible approach available every inspection time. Therefore, our present study aimed to investigate expression patterns of potentially circulating biomarkers that can differentiate well between benign, malignant, and healthy subjects.
Methods
To achieve our target, quantitative analyses were performed for some circulating biomarkers which have a role in the proliferation and tumor growth, as well as, glutamic acid, and human epidermal growth receptor 2 (HER2) in blood samples of BC patients in comparison to healthy controls using qRT-PCR, liquid chromatography/mass spectrometry (LC/MS/MS), and ELISA.
Results
Our findings showed that the two miRNAs (miRNA-145, miRNA-382) were expressed at lower levels in BC sera than healthy control group, while miRNA-21 was expressed at higher levels in BC patients than control subjects. Area under ROC curves of BC samples revealed that AUC of miRNA-145, miRNA-382, miRNA-21, and glutamic acid was evaluated to equal 0.99, 1.00, 1.00 and 1.00, respectively. Besides, there was a significantly positive correlation between miRNA-145 and miRNA-382 (
r
= 0.737), and a highly significant positive correlation between miRNA-21 and glutamic acid (
r
= 0.385).
Conclusion
Based on our results, we conclude that the detection of serum miRNA-145, -382 and -21 as a panel along with glutamic acid, and circulating HER2 concentrations could be useful as a non-invasive diagnostic profiling for early prediction of breast cancer in Egyptian patients. It can provide an insight into disease progression, discriminate between malignancy and healthy control, and overcome the use limitations (low sensitivity and specificity, repeated risky exposure, and high cost) of other detecting tools, including mammography, magnetic resonance imaging, and ultrasound. |
doi_str_mv | 10.1007/s00432-022-04492-2 |
format | Article |
fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10349790</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2837644979</sourcerecordid><originalsourceid>FETCH-LOGICAL-c475t-17023d798bbeb89c7746d8e18a9abe327c8170ad93d6389b0626f8352d36abc13</originalsourceid><addsrcrecordid>eNp9kUtv1TAQhS0EopfCH2CBLLFhE-pHEscrVFXlIVVFQmVtOfYkdZXYF9spusv-8zq9paUsWFiW53xzPKOD0FtKPlJCxFEipOasIqycupasYs_Qhq4lynnzHG0IFbRqGG0P0KuUrkh5N4K9RAe8rRvJJNmgm4tLwNbp0YeUncHJjd4NzmhvAIcBGxfNMuns_Ihn9-P8OGHtLZ4h6z5MLgPexjC4adWdx6DjtCslsM5kF_xq0UfQKeM7y7hCp-Num532-HeYwb9GLwY9JXhzfx-in59PL06-Vmffv3w7OT6rTC2aXFFBGLdCdn0PfSeNEHVrO6CdlroHzoTpCqKt5LblnexJy9qh4w2zvNW9ofwQfdr7bpd-BmvA56gntY1u1nGngnbqqeLdpRrDtaKE11JIUhw-3DvE8GuBlNXskoFp0h7CkhQrI3HJaL2i7_9Br8ISfdlPsY6Ltl4dC8X2lIkhpQjDwzSUqDVitY9YlYjVXcSKlaZ3f-_x0PIn0wLwPZCK5EeIj3__x_YWl3Wzog</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2837644979</pqid></control><display><type>article</type><title>The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women</title><source>SpringerLink Journals - AutoHoldings</source><creator>El-Toukhy, Safinaz E. ; El-Daly, Sherien M. ; Kamel, Mahmoud M. ; Nabih, Heba K.</creator><creatorcontrib>El-Toukhy, Safinaz E. ; El-Daly, Sherien M. ; Kamel, Mahmoud M. ; Nabih, Heba K.</creatorcontrib><description>Objective
Breast cancer (BC) is one of the most commonly diagnosed solid malignancies in women worldwide.
Purpose
Finding new non-invasive circulating diagnostic biomarkers will facilitate the early prediction of BC and provide valuable insight into disease progression and response to therapy using a safe and more accessible approach available every inspection time. Therefore, our present study aimed to investigate expression patterns of potentially circulating biomarkers that can differentiate well between benign, malignant, and healthy subjects.
Methods
To achieve our target, quantitative analyses were performed for some circulating biomarkers which have a role in the proliferation and tumor growth, as well as, glutamic acid, and human epidermal growth receptor 2 (HER2) in blood samples of BC patients in comparison to healthy controls using qRT-PCR, liquid chromatography/mass spectrometry (LC/MS/MS), and ELISA.
Results
Our findings showed that the two miRNAs (miRNA-145, miRNA-382) were expressed at lower levels in BC sera than healthy control group, while miRNA-21 was expressed at higher levels in BC patients than control subjects. Area under ROC curves of BC samples revealed that AUC of miRNA-145, miRNA-382, miRNA-21, and glutamic acid was evaluated to equal 0.99, 1.00, 1.00 and 1.00, respectively. Besides, there was a significantly positive correlation between miRNA-145 and miRNA-382 (
r
= 0.737), and a highly significant positive correlation between miRNA-21 and glutamic acid (
r
= 0.385).
Conclusion
Based on our results, we conclude that the detection of serum miRNA-145, -382 and -21 as a panel along with glutamic acid, and circulating HER2 concentrations could be useful as a non-invasive diagnostic profiling for early prediction of breast cancer in Egyptian patients. It can provide an insight into disease progression, discriminate between malignancy and healthy control, and overcome the use limitations (low sensitivity and specificity, repeated risky exposure, and high cost) of other detecting tools, including mammography, magnetic resonance imaging, and ultrasound.</description><identifier>ISSN: 0171-5216</identifier><identifier>EISSN: 1432-1335</identifier><identifier>DOI: 10.1007/s00432-022-04492-2</identifier><identifier>PMID: 36459290</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Acids ; Biomarkers ; Breast cancer ; Cancer Research ; ErbB-2 protein ; Glutamic acid ; Hematology ; Internal Medicine ; Invasiveness ; Liquid chromatography ; Magnetic resonance imaging ; Malignancy ; Mammography ; Mass spectroscopy ; Medicine ; Medicine & Public Health ; MicroRNAs ; miRNA ; Oncology ; Predictions</subject><ispartof>Journal of cancer research and clinical oncology, 2023-07, Vol.149 (8), p.5437-5451</ispartof><rights>The Author(s) 2022</rights><rights>2022. The Author(s).</rights><rights>The Author(s) 2022. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c475t-17023d798bbeb89c7746d8e18a9abe327c8170ad93d6389b0626f8352d36abc13</citedby><cites>FETCH-LOGICAL-c475t-17023d798bbeb89c7746d8e18a9abe327c8170ad93d6389b0626f8352d36abc13</cites><orcidid>0000-0003-0049-8606 ; 0000-0001-7617-9965 ; 0000-0002-4660-8404 ; 0000-0003-0264-3096</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00432-022-04492-2$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00432-022-04492-2$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,315,781,785,886,27929,27930,41493,42562,51324</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36459290$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>El-Toukhy, Safinaz E.</creatorcontrib><creatorcontrib>El-Daly, Sherien M.</creatorcontrib><creatorcontrib>Kamel, Mahmoud M.</creatorcontrib><creatorcontrib>Nabih, Heba K.</creatorcontrib><title>The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women</title><title>Journal of cancer research and clinical oncology</title><addtitle>J Cancer Res Clin Oncol</addtitle><addtitle>J Cancer Res Clin Oncol</addtitle><description>Objective
Breast cancer (BC) is one of the most commonly diagnosed solid malignancies in women worldwide.
Purpose
Finding new non-invasive circulating diagnostic biomarkers will facilitate the early prediction of BC and provide valuable insight into disease progression and response to therapy using a safe and more accessible approach available every inspection time. Therefore, our present study aimed to investigate expression patterns of potentially circulating biomarkers that can differentiate well between benign, malignant, and healthy subjects.
Methods
To achieve our target, quantitative analyses were performed for some circulating biomarkers which have a role in the proliferation and tumor growth, as well as, glutamic acid, and human epidermal growth receptor 2 (HER2) in blood samples of BC patients in comparison to healthy controls using qRT-PCR, liquid chromatography/mass spectrometry (LC/MS/MS), and ELISA.
Results
Our findings showed that the two miRNAs (miRNA-145, miRNA-382) were expressed at lower levels in BC sera than healthy control group, while miRNA-21 was expressed at higher levels in BC patients than control subjects. Area under ROC curves of BC samples revealed that AUC of miRNA-145, miRNA-382, miRNA-21, and glutamic acid was evaluated to equal 0.99, 1.00, 1.00 and 1.00, respectively. Besides, there was a significantly positive correlation between miRNA-145 and miRNA-382 (
r
= 0.737), and a highly significant positive correlation between miRNA-21 and glutamic acid (
r
= 0.385).
Conclusion
Based on our results, we conclude that the detection of serum miRNA-145, -382 and -21 as a panel along with glutamic acid, and circulating HER2 concentrations could be useful as a non-invasive diagnostic profiling for early prediction of breast cancer in Egyptian patients. It can provide an insight into disease progression, discriminate between malignancy and healthy control, and overcome the use limitations (low sensitivity and specificity, repeated risky exposure, and high cost) of other detecting tools, including mammography, magnetic resonance imaging, and ultrasound.</description><subject>Acids</subject><subject>Biomarkers</subject><subject>Breast cancer</subject><subject>Cancer Research</subject><subject>ErbB-2 protein</subject><subject>Glutamic acid</subject><subject>Hematology</subject><subject>Internal Medicine</subject><subject>Invasiveness</subject><subject>Liquid chromatography</subject><subject>Magnetic resonance imaging</subject><subject>Malignancy</subject><subject>Mammography</subject><subject>Mass spectroscopy</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>MicroRNAs</subject><subject>miRNA</subject><subject>Oncology</subject><subject>Predictions</subject><issn>0171-5216</issn><issn>1432-1335</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNp9kUtv1TAQhS0EopfCH2CBLLFhE-pHEscrVFXlIVVFQmVtOfYkdZXYF9spusv-8zq9paUsWFiW53xzPKOD0FtKPlJCxFEipOasIqycupasYs_Qhq4lynnzHG0IFbRqGG0P0KuUrkh5N4K9RAe8rRvJJNmgm4tLwNbp0YeUncHJjd4NzmhvAIcBGxfNMuns_Ihn9-P8OGHtLZ4h6z5MLgPexjC4adWdx6DjtCslsM5kF_xq0UfQKeM7y7hCp-Num532-HeYwb9GLwY9JXhzfx-in59PL06-Vmffv3w7OT6rTC2aXFFBGLdCdn0PfSeNEHVrO6CdlroHzoTpCqKt5LblnexJy9qh4w2zvNW9ofwQfdr7bpd-BmvA56gntY1u1nGngnbqqeLdpRrDtaKE11JIUhw-3DvE8GuBlNXskoFp0h7CkhQrI3HJaL2i7_9Br8ISfdlPsY6Ltl4dC8X2lIkhpQjDwzSUqDVitY9YlYjVXcSKlaZ3f-_x0PIn0wLwPZCK5EeIj3__x_YWl3Wzog</recordid><startdate>20230701</startdate><enddate>20230701</enddate><creator>El-Toukhy, Safinaz E.</creator><creator>El-Daly, Sherien M.</creator><creator>Kamel, Mahmoud M.</creator><creator>Nabih, Heba K.</creator><general>Springer Berlin Heidelberg</general><general>Springer Nature B.V</general><scope>C6C</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7TO</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M2O</scope><scope>MBDVC</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-0049-8606</orcidid><orcidid>https://orcid.org/0000-0001-7617-9965</orcidid><orcidid>https://orcid.org/0000-0002-4660-8404</orcidid><orcidid>https://orcid.org/0000-0003-0264-3096</orcidid></search><sort><creationdate>20230701</creationdate><title>The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women</title><author>El-Toukhy, Safinaz E. ; El-Daly, Sherien M. ; Kamel, Mahmoud M. ; Nabih, Heba K.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c475t-17023d798bbeb89c7746d8e18a9abe327c8170ad93d6389b0626f8352d36abc13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Acids</topic><topic>Biomarkers</topic><topic>Breast cancer</topic><topic>Cancer Research</topic><topic>ErbB-2 protein</topic><topic>Glutamic acid</topic><topic>Hematology</topic><topic>Internal Medicine</topic><topic>Invasiveness</topic><topic>Liquid chromatography</topic><topic>Magnetic resonance imaging</topic><topic>Malignancy</topic><topic>Mammography</topic><topic>Mass spectroscopy</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>MicroRNAs</topic><topic>miRNA</topic><topic>Oncology</topic><topic>Predictions</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>El-Toukhy, Safinaz E.</creatorcontrib><creatorcontrib>El-Daly, Sherien M.</creatorcontrib><creatorcontrib>Kamel, Mahmoud M.</creatorcontrib><creatorcontrib>Nabih, Heba K.</creatorcontrib><collection>Springer Nature OA/Free Journals</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Research Library</collection><collection>Research Library (Corporate)</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of cancer research and clinical oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>El-Toukhy, Safinaz E.</au><au>El-Daly, Sherien M.</au><au>Kamel, Mahmoud M.</au><au>Nabih, Heba K.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women</atitle><jtitle>Journal of cancer research and clinical oncology</jtitle><stitle>J Cancer Res Clin Oncol</stitle><addtitle>J Cancer Res Clin Oncol</addtitle><date>2023-07-01</date><risdate>2023</risdate><volume>149</volume><issue>8</issue><spage>5437</spage><epage>5451</epage><pages>5437-5451</pages><issn>0171-5216</issn><eissn>1432-1335</eissn><abstract>Objective
Breast cancer (BC) is one of the most commonly diagnosed solid malignancies in women worldwide.
Purpose
Finding new non-invasive circulating diagnostic biomarkers will facilitate the early prediction of BC and provide valuable insight into disease progression and response to therapy using a safe and more accessible approach available every inspection time. Therefore, our present study aimed to investigate expression patterns of potentially circulating biomarkers that can differentiate well between benign, malignant, and healthy subjects.
Methods
To achieve our target, quantitative analyses were performed for some circulating biomarkers which have a role in the proliferation and tumor growth, as well as, glutamic acid, and human epidermal growth receptor 2 (HER2) in blood samples of BC patients in comparison to healthy controls using qRT-PCR, liquid chromatography/mass spectrometry (LC/MS/MS), and ELISA.
Results
Our findings showed that the two miRNAs (miRNA-145, miRNA-382) were expressed at lower levels in BC sera than healthy control group, while miRNA-21 was expressed at higher levels in BC patients than control subjects. Area under ROC curves of BC samples revealed that AUC of miRNA-145, miRNA-382, miRNA-21, and glutamic acid was evaluated to equal 0.99, 1.00, 1.00 and 1.00, respectively. Besides, there was a significantly positive correlation between miRNA-145 and miRNA-382 (
r
= 0.737), and a highly significant positive correlation between miRNA-21 and glutamic acid (
r
= 0.385).
Conclusion
Based on our results, we conclude that the detection of serum miRNA-145, -382 and -21 as a panel along with glutamic acid, and circulating HER2 concentrations could be useful as a non-invasive diagnostic profiling for early prediction of breast cancer in Egyptian patients. It can provide an insight into disease progression, discriminate between malignancy and healthy control, and overcome the use limitations (low sensitivity and specificity, repeated risky exposure, and high cost) of other detecting tools, including mammography, magnetic resonance imaging, and ultrasound.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>36459290</pmid><doi>10.1007/s00432-022-04492-2</doi><tpages>15</tpages><orcidid>https://orcid.org/0000-0003-0049-8606</orcidid><orcidid>https://orcid.org/0000-0001-7617-9965</orcidid><orcidid>https://orcid.org/0000-0002-4660-8404</orcidid><orcidid>https://orcid.org/0000-0003-0264-3096</orcidid><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0171-5216 |
ispartof | Journal of cancer research and clinical oncology, 2023-07, Vol.149 (8), p.5437-5451 |
issn | 0171-5216 1432-1335 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10349790 |
source | SpringerLink Journals - AutoHoldings |
subjects | Acids Biomarkers Breast cancer Cancer Research ErbB-2 protein Glutamic acid Hematology Internal Medicine Invasiveness Liquid chromatography Magnetic resonance imaging Malignancy Mammography Mass spectroscopy Medicine Medicine & Public Health MicroRNAs miRNA Oncology Predictions |
title | The diagnostic significance of circulating miRNAs and metabolite profiling in early prediction of breast cancer in Egyptian women |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-10T02%3A18%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20diagnostic%20significance%20of%20circulating%20miRNAs%20and%20metabolite%20profiling%20in%20early%20prediction%20of%20breast%20cancer%20in%20Egyptian%20women&rft.jtitle=Journal%20of%20cancer%20research%20and%20clinical%20oncology&rft.au=El-Toukhy,%20Safinaz%20E.&rft.date=2023-07-01&rft.volume=149&rft.issue=8&rft.spage=5437&rft.epage=5451&rft.pages=5437-5451&rft.issn=0171-5216&rft.eissn=1432-1335&rft_id=info:doi/10.1007/s00432-022-04492-2&rft_dat=%3Cproquest_pubme%3E2837644979%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2837644979&rft_id=info:pmid/36459290&rfr_iscdi=true |